A detailed history of Vanguard Group Inc transactions in Glycomimetics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 2,696,906 shares of GLYC stock, worth $1.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,696,906
Previous 2,761,981 2.36%
Holding current value
$1.13 Million
Previous $8.29 Million 90.89%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.24 - $3.04 $15,618 - $197,828
-65,075 Reduced 2.36%
2,696,906 $755,000
Q1 2024

May 10, 2024

BUY
$2.55 - $3.49 $867,285 - $1.19 Million
340,112 Added 14.04%
2,761,981 $8.29 Million
Q3 2023

Nov 14, 2023

BUY
$1.29 - $1.73 $138,628 - $185,912
107,464 Added 4.64%
2,421,869 $3.63 Million
Q2 2023

Aug 14, 2023

SELL
$1.21 - $2.08 $177,177 - $304,570
-146,428 Reduced 5.95%
2,314,405 $4.03 Million
Q1 2023

May 15, 2023

BUY
$1.25 - $4.05 $231,400 - $749,736
185,120 Added 8.13%
2,460,833 $3.1 Million
Q4 2022

Feb 10, 2023

BUY
$0.57 - $3.03 $225,891 - $1.2 Million
396,301 Added 21.09%
2,275,713 $6.9 Million
Q3 2022

Nov 14, 2022

BUY
$0.55 - $0.9 $17,957 - $29,385
32,650 Added 1.77%
1,879,412 $1.04 Million
Q2 2022

Aug 12, 2022

BUY
$0.54 - $1.15 $17,171 - $36,568
31,799 Added 1.75%
1,846,762 $1.11 Million
Q1 2022

May 13, 2022

SELL
$1.0 - $1.58 $423,590 - $669,272
-423,590 Reduced 18.92%
1,814,963 $2.07 Million
Q4 2021

Feb 14, 2022

SELL
$1.44 - $2.14 $30,903 - $45,926
-21,461 Reduced 0.95%
2,238,553 $3.22 Million
Q3 2021

Nov 12, 2021

SELL
$1.8 - $2.39 $18,797 - $24,958
-10,443 Reduced 0.46%
2,260,014 $4.95 Million
Q2 2021

Aug 13, 2021

BUY
$2.16 - $3.18 $4.9 Million - $7.22 Million
2,270,457 New
2,270,457 $5.27 Million

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $22M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.